Menu
close
Please contact us for more information or to learn if you are eligible to participate.
The primary objective is to determine the efficacy and safety profiles of EYP001a versus placebo on liver fat content (LFC) from baseline to Week 12 in patient with NASH.
Principal Investigator | Marcel B. Twahirwa, MD |
Co-PI | John Rodriguez |
Sponsor | Enyo Pharma |
Type of Trial | Interventional |